Xiao Lianchen, Huang Yanning, Sun Hui, Gao Sai, Huang Dehui, Wu Lei
Department of Neurology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, China.
Department of Neurology, Chinese PLA General Hospital, Beijing, China.
Acta Neurol Belg. 2024 Dec;124(6):1847-1854. doi: 10.1007/s13760-024-02555-4. Epub 2024 Jun 11.
Some patients with neuromyelitis optica spectrum disorder (NMOSD) experience relapse after rituximab (RTX) treatment. In this retrospective study, we analyzed the recurrence-related clinical features, laboratory investigation results, and dosing protocol of 30 female patients with relapsing NMOSD with immunoglobulin G autoantibodies against aquaporin-4 and relapses during repeated 0.5 g RTX infusions as maintenance treatment. The median follow-up period was 6.62 years. Thirty-five episodes were observed, with myelitis being the most frequent. The median expanded disability status scale change score was 0.50. The recurrence rate decreased by 44.23%/year with RTX infusion. Approximately 85.71% of the patients showed relapse without RTX infusion within 10 months. Overall, RTX may be effective for relapsing NMOSD cases.
一些视神经脊髓炎谱系障碍（NMOSD）患者在接受利妥昔单抗（RTX）治疗后会复发。在这项回顾性研究中，我们分析了30例复发型NMOSD女性患者的复发相关临床特征、实验室检查结果以及给药方案，这些患者均有抗水通道蛋白4免疫球蛋白G自身抗体，且在重复静脉输注0.5g RTX作为维持治疗期间出现复发。中位随访期为6.62年。共观察到35次发作，其中脊髓炎最为常见。扩展残疾状态量表变化评分中位数为0.50。RTX输注使复发率每年降低44.23%。约85.71%的患者在10个月内未输注RTX时出现复发。总体而言，RTX可能对复发型NMOSD病例有效。
